Drug Trial Radar · NCT04567303
Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
177
Actual
Start
Oct 28, 2020
Primary completion
Aug 25, 2026
Study completion Aug 25, 2026
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).
Conditions
- Macular Degeneration
Interventions
ZifibancimigDrug
Part 1: multiple ascending doses by IVT injection. Each participant will receive zifibancimig at a constant volume of 50 microliter (µL) in the study eye. Part 2: participants will be randomized to one of two dose levels of zifibancimig in the PD implant. Part 3: Participants will receive one of the two dose levels of zifibancimig in the PD implant.
RanibizumabDrug
Participants will receive ranibizumab 100 mg/mL through the PD implant
Port Delivery PlatformDevice
Participants will receive intraocular refillable device that is surgically inserted into the eye for continuous delivery of drugs into the vitreous.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Ocular and Systemic (Non-ocular) Adverse Events (AEs)Time frame: Part 1: Baseline up to Week 24; Parts 2 & 3: Baseline up to Week 48
- Percentage of Participants With Ocular AEs During the Post-operative and Follow-up PeriodsTime frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)
- Percentage of Participants With Adverse Events of Special Interest (AESIs) Including Ocular AESIsTime frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 48
- Percentage of Participants With Ocular AESIs During the Post-operative and Follow-up PeriodsTime frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)
- Duration of Ocular AESIsTime frame: Part 1: Baseline up to Week 24; Parts 2 and 3: Baseline up to Week 48
- Duration of Ocular AESIs During the Post-operative and Follow-up PeriodsTime frame: Parts 2 and 3: From Day 1 to Week 4 and during follow-up period (up to Week 48)
- Percentage of Participants With Adverse Device Effects (ADEs)Time frame: Parts 2 and 3: Baseline up to Week 48
- Duration of ADEsTime frame: Parts 2 and 3: Baseline up to Week 48
- Percentage of Participants With Anticipated Serious ADEs (ASADEs)Time frame: Parts 2 and 3: Baseline up to Week 48
- Duration of ASADEsTime frame: Parts 2 and 3: Baseline up to Week 48
- Change From Baseline in Early Treatment Diabetic Retinopathy Study - Best Corrected Visual Acuity (ETDRS-BCVA) Score at Week 48Time frame: Part 3: Baseline (baseline visit, before implant insertion), and Week 48
Locations
37 sites in 2 countries. Site status is shown where the registry gives one.
Barnet Dulaney Perkins Eye Center
Mesa, Arizona
Associated Retina Consultants
Phoenix, Arizona
The Retina Partners
Encino, California
Retinal Consultants Med Group
Sacramento, California
Orange County Retina Med Group
Santa Ana, California
Southwest Retina Consultants
Durango, Colorado
Retina Vitreous Assoc of FL
St. Petersburg, Florida
Southern Vitreoretinal Assoc
Tallahassee, Florida
Southeast Retina Center
Augusta, Georgia
University Retina and Macula Associates, PC
Oak Forest, Illinois
Maine Eye Center
Portland, Maine
Johns Hopkins Med
Baltimore, Maryland
Retina Group of Washington
Chevy Chase, Maryland
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Foundation for Vision Research
Grand Rapids, Michigan
Associated Retinal Consultants
Royal Oak, Michigan
VitreoRetinal Surgery, PLLC.
Saint Louis Park, Minnesota
The Retina Institute
St Louis, Missouri
Sierra Eye Associates
Reno, Nevada
Envision Ocular, LLC
Bloomfield, New Jersey
Retina Vit Surgeons/Central NY
Liverpool, New York
Duke Eye Center
Durham, North Carolina
Graystone Eye
Hickory, North Carolina
OSU Eye Physicians & Surgeons
Columbus, Ohio
Mid Atlantic Retina - Wills Eye Hospital
Philadelphia, Pennsylvania
Carolina Eyecare Physicians
Mt. Pleasant, South Carolina
Charles Retina Institute
Germantown, Tennessee
Southeastern Retina Associates
Knoxville, Tennessee
Tennessee Retina PC.
Nashville, Tennessee
Austin Research Center for Retina
Austin, Texas
Austin Clinical Research LLC
Austin, Texas
Retina Consultants of Texas
Bellaire, Texas
Retina Consultants of Texas
Houston, Texas
Retina Center of Texas
Southlake, Texas
Piedmont Eye Center
Lynchburg, Virginia
Spokane Eye Clinical Research
Spokane, Washington
Emanuelli Research and Development Center LLC
Arecibo, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.